CN102351844B - 泮托拉唑钠化合物及其药物组合物 - Google Patents
泮托拉唑钠化合物及其药物组合物 Download PDFInfo
- Publication number
- CN102351844B CN102351844B CN201110228921XA CN201110228921A CN102351844B CN 102351844 B CN102351844 B CN 102351844B CN 201110228921X A CN201110228921X A CN 201110228921XA CN 201110228921 A CN201110228921 A CN 201110228921A CN 102351844 B CN102351844 B CN 102351844B
- Authority
- CN
- China
- Prior art keywords
- pantoprazole sodium
- freeze
- drying
- compound
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960004048 pantoprazole sodium Drugs 0.000 title claims abstract description 138
- YNWDKZIIWCEDEE-UHFFFAOYSA-N pantoprazole sodium Chemical compound [Na+].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC YNWDKZIIWCEDEE-UHFFFAOYSA-N 0.000 title claims abstract description 138
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 31
- 238000004108 freeze drying Methods 0.000 claims abstract description 73
- 239000000843 powder Substances 0.000 claims abstract description 70
- 238000002360 preparation method Methods 0.000 claims abstract description 44
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 40
- 239000013078 crystal Substances 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 25
- 230000008901 benefit Effects 0.000 claims abstract description 19
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 68
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 68
- 239000000243 solution Substances 0.000 claims description 65
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 38
- 238000003756 stirring Methods 0.000 claims description 35
- 239000000047 product Substances 0.000 claims description 26
- 238000001914 filtration Methods 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- 238000001035 drying Methods 0.000 claims description 21
- 239000008215 water for injection Substances 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 17
- 239000012065 filter cake Substances 0.000 claims description 16
- 238000001291 vacuum drying Methods 0.000 claims description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
- 229930195725 Mannitol Natural products 0.000 claims description 13
- 239000000594 mannitol Substances 0.000 claims description 13
- 235000010355 mannitol Nutrition 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 12
- -1 filter Substances 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 9
- 229910017488 Cu K Inorganic materials 0.000 claims description 8
- 229910017541 Cu-K Inorganic materials 0.000 claims description 8
- 230000005260 alpha ray Effects 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 238000007710 freezing Methods 0.000 claims description 7
- 230000008014 freezing Effects 0.000 claims description 7
- 238000009413 insulation Methods 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 239000000890 drug combination Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 10
- 239000007924 injection Substances 0.000 abstract description 7
- 238000002347 injection Methods 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 6
- 239000003978 infusion fluid Substances 0.000 abstract description 5
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- 239000012535 impurity Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 238000005259 measurement Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 23
- 238000012360 testing method Methods 0.000 description 15
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 13
- 238000002425 crystallisation Methods 0.000 description 13
- 229960005019 pantoprazole Drugs 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000008025 crystallization Effects 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 9
- 208000007107 Stomach Ulcer Diseases 0.000 description 7
- 201000005917 gastric ulcer Diseases 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000008354 sodium chloride injection Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 235000014347 soups Nutrition 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011082 depyrogenation Methods 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000002411 thermogravimetry Methods 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000005357 flat glass Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
处方编号 | 失重(%) | 温度范围(℃) | 结晶水理论值(%) |
实施例1 | 4.21 | 180-210 | 4.25 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110228921XA CN102351844B (zh) | 2011-08-11 | 2011-08-11 | 泮托拉唑钠化合物及其药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110228921XA CN102351844B (zh) | 2011-08-11 | 2011-08-11 | 泮托拉唑钠化合物及其药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102351844A CN102351844A (zh) | 2012-02-15 |
CN102351844B true CN102351844B (zh) | 2012-08-15 |
Family
ID=45575513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110228921XA Expired - Fee Related CN102351844B (zh) | 2011-08-11 | 2011-08-11 | 泮托拉唑钠化合物及其药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102351844B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102626398A (zh) * | 2012-04-18 | 2012-08-08 | 上海腾瑞制药有限公司 | 一种泮托拉唑钠肠溶片及其制备方法 |
CN102846559B (zh) * | 2012-09-20 | 2014-07-09 | 浙江亚太药业股份有限公司 | 一种泮托拉唑钠冻干制剂及其制备方法 |
CN103054797B (zh) * | 2013-01-23 | 2014-02-26 | 海南锦瑞制药股份有限公司 | 一种泮托拉唑钠的药物组合物及其制备方法 |
CN104856993A (zh) * | 2015-05-26 | 2015-08-26 | 苗怡文 | 治疗消化系统疾病的药物泮托拉唑钠冻干粉针剂组合物 |
CN104958265A (zh) * | 2015-08-05 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗消化系统疾病的药物泮托拉唑钠组合物颗粒剂 |
CN107550871B (zh) * | 2017-08-30 | 2020-07-21 | 杭州中美华东制药有限公司 | 一种含泮托拉唑钠的冻干组合物 |
CN113125583B (zh) * | 2019-12-30 | 2022-06-21 | 成都百裕制药股份有限公司 | 一种注射用泮托拉唑钠中基因毒性杂质含量的检测方法 |
CN112587486B (zh) * | 2020-12-29 | 2022-05-13 | 南京健友生化制药股份有限公司 | 一种注射用泮托拉唑钠冻干粉针及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991019710A1 (de) * | 1990-06-11 | 1991-12-26 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue salzform |
CN101229138A (zh) * | 2008-01-18 | 2008-07-30 | 山东罗欣药业股份有限公司 | 一种泮托拉唑钠冻干粉针剂及其制备方法 |
US7507829B2 (en) * | 2002-12-19 | 2009-03-24 | Teva Pharmaceuticals Industries, Ltd | Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates |
-
2011
- 2011-08-11 CN CN201110228921XA patent/CN102351844B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991019710A1 (de) * | 1990-06-11 | 1991-12-26 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue salzform |
US7507829B2 (en) * | 2002-12-19 | 2009-03-24 | Teva Pharmaceuticals Industries, Ltd | Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates |
CN101229138A (zh) * | 2008-01-18 | 2008-07-30 | 山东罗欣药业股份有限公司 | 一种泮托拉唑钠冻干粉针剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102351844A (zh) | 2012-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102351844B (zh) | 泮托拉唑钠化合物及其药物组合物 | |
AU2008215384B2 (en) | Crystalline forms of thiazolidinedione compound and its manufacturing method | |
CN103087042B (zh) | 西他沙星的盐及制药用途 | |
CN101177433A (zh) | 左旋奥硝唑磷酸二钠五水合物及其制备方法和用途 | |
SA99191115B1 (ar) | مركبات صيدلية جديدة | |
CN105777633A (zh) | 四氢异喹啉类衍生物及其应用 | |
CN102198134B (zh) | 一种新型稳定的尤利沙星盐酸盐在制备抗感染药物中的应用 | |
CN103462910A (zh) | 一种注射用阿奇霉素组合物及其制备方法 | |
CN102670524B (zh) | 一种注射用泮托拉唑钠冻干制剂及其制备方法 | |
CN104086531B (zh) | 一种埃索美拉唑钠化合物及其药物组合物 | |
CN103304424B (zh) | 一种二氯醋酸二异丙胺化合物及其复方药物组合物注射剂 | |
CN102757471B (zh) | 一种新活性三磷酸胞苷二钠化合物及其药物组合物 | |
CN1321997C (zh) | 一种稳定的噻丁啶喹啉羧酸盐在制备抗感染药物中的应用 | |
CN103040737A (zh) | 一种含有兰索拉唑化合物的药物组合物及其制备方法 | |
US4322424A (en) | Crystalline glucoconate salt of m-AMSA and compositions containing same | |
CN102198136B (zh) | 一种新型稳定的尤利沙星甲磺酸盐在制备抗感染药物中的应用 | |
CN102475704B (zh) | 一种稳定的普卢利沙星甲磺酸盐的制备方法 | |
CN101492452B (zh) | 含有二氧杂环庚烷并吡啶的巯基苯并咪唑衍生物 | |
CN102198135B (zh) | 一种新型稳定的普卢利沙星盐酸盐在制备抗感染药物中的应用 | |
CN101492464B (zh) | 含有二氧杂环庚烷并吡啶的巯基咪唑并吡啶衍生物 | |
CN101492463B (zh) | 含有二氧杂环并吡啶的咪唑并吡啶衍生物 | |
CN101497622B (zh) | 吡啶甲基亚磺酰基咪唑并吡啶衍生物 | |
CN101492460B (zh) | 含烷氧烷基取代的吡啶并四氢异噁唑的苯并咪唑衍生物 | |
CN101492459B (zh) | 含烷氧乙酰基二氢异噁唑并吡啶化合物 | |
CN101497623B (zh) | 含有咪唑并吡啶的化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120215 Assignee: SHANXI WEIQIDA GUANGMING PHARMACEUTICAL Co.,Ltd. Assignor: Jiangxi Xinxianfeng Medical Co.,Ltd. Contract record no.: 2013990000027 Denomination of invention: Pantoprazole sodium compound and pharmaceutical composition thereof Granted publication date: 20120815 License type: Common License Record date: 20130122 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120215 Assignee: CHENGDU TONGDE PHARMACEUTICAL Co.,Ltd. Assignor: Jiangxi Xinxianfeng Medical Co.,Ltd. Contract record no.: 2013360000131 Denomination of invention: Pantoprazole sodium compound and pharmaceutical composition thereof Granted publication date: 20120815 License type: Common License Record date: 20130929 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120215 Assignee: CHENGDU TONGDE PHARMACEUTICAL Co.,Ltd. Assignor: Jiangxi Xinxianfeng Medical Co.,Ltd. Contract record no.: 2015360000148 Denomination of invention: Pantoprazole sodium compound and pharmaceutical composition thereof Granted publication date: 20120815 License type: Common License Record date: 20151209 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120815 |